Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 0.37 |
| ▸ | HTR2A | P28223 | 14/20 | 0.37 |
| ▸ | DRD3 | P35462 | 14/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3798049 | 0.77 | EED (0.37) | DRD2HTR2ADRD3 | |
| SCHEMBL125014 | 0.75 | MTNR1A (0.50) | MTNR1BMTNR1A | |
| SCHEMBL123730 | 0.74 | HTR2A (0.36) | DRD2HTR2ADRD3 | |
| SCHEMBL6948957 | 0.74 | MTNR1A (0.48) | MTNR1BMTNR1ASLC9A1 | |
| SCHEMBL3793545 | 0.73 | DRD1 (0.35) | DRD2HTR2ADRD3 | |
| SCHEMBL6955724 | 0.72 | EED (0.42) | — | |
| SCHEMBL6956175 | 0.72 | MTNR1B (0.37) | MAP3K14MTNR1BMTNR1ASLC9A1 | |
| SCHEMBL6955159 | 0.72 | MTNR1B (0.42) | MAP3K14MTNR1BMTNR1ASLC9A1 | |
| SCHEMBL9789848 | 0.68 | CTNNB1 (0.35) | HTR2AMTNR1BMTNR1A | |
| SCHEMBL24529108 | 0.68 | NOS3 (0.46) | DRD2HTR2ADRD3SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273761-B2 | Tricyclic compound and medical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273761-B2 | Tricyclic compound and medical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273761-B2 | Tricyclic compound and medical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2100895-B1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-03-07 | — | — | EP | disclosed |
| EP-2100895-B1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100029707-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029707-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029707-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2100895-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-09-16 | — | — | EP | disclosed |
| EP-2100895-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029707-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | MTNR1A, MTNR1B, AHR | DRD2 245/4885HTR2A 15/4885DRD3 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.